

# Christopher C Benz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/229178/publications.pdf>

Version: 2024-02-01

83  
papers

21,681  
citations

66343

42  
h-index

58581

82  
g-index

85  
all docs

85  
docs citations

85  
times ranked

31700  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 451-458.	2.5	2
2	Clinical and molecular characteristics of estrogen receptor- $\alpha$ -positive ultralow risk breast cancer tumors identified by the 70-gene signature. <i>International Journal of Cancer</i> , 2022, 150, 2072-2082.	5.1	7
3	Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. <i>JAMA Network Open</i> , 2021, 4, e2114716.	5.9	14
4	N-Propargylglycine: a unique suicide inhibitor of proline dehydrogenase with anticancer activity and brain-enhancing mitohormesis properties. <i>Amino Acids</i> , 2021, 53, 1927-1939.	2.7	5
5	Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy. <i>JAMA Network Open</i> , 2021, 4, e2114904.	5.9	12
6	A risk-associated Active transcriptome phenotype expressed by histologically normal human breast tissue and linked to a pro-tumorigenic adipocyte population. <i>Breast Cancer Research</i> , 2020, 22, 81.	5.0	12
7	Cancer and Cardiovascular Risk in Women With Hypertensive Disorders of Pregnancy Carrying a Common IGF1R Variant. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2684-2696.	3.0	3
8	Pregnancy Hypertension and a Commonly Inherited IGF1R Variant (rs2016347) Reduce Breast Cancer Risk by Enhancing Mammary Gland Involution. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	1.3	6
9	Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1374-1385.	4.1	26
10	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , 2018, 173, 400-416.e11.	28.9	2,277
11	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	28.9	1,670
12	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , 2018, 173, 291-304.e6.	28.9	1,718
13	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , 2018, 173, 305-320.e10.	28.9	272
14	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , 2018, 173, 338-354.e15.	28.9	1,417
15	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , 2018, 173, 321-337.e10.	28.9	2,111
16	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , 2018, 23, 194-212.e6.	6.4	245
17	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , 2018, 23, 213-226.e3.	6.4	83
18	Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype. <i>Scientific Reports</i> , 2018, 8, 2410.	3.3	93

#	ARTICLE	IF	CITATIONS
19	Discovery of internalizing antibodies to basal breast cancer cells. <i>Protein Engineering, Design and Selection</i> , 2018, 31, 17-28.	2.1	4
20	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , 2018, 33, 676-689.e3.	16.8	750
21	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , 2018, 33, 721-735.e8.	16.8	396
22	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , 2018, 33, 690-705.e9.	16.8	478
23	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , 2018, 34, 211-224.e6.	16.8	623
24	Functional IGF1R variant predicts breast cancer risk in women with preeclampsia in California Teachers Study. <i>Cancer Causes and Control</i> , 2017, 28, 1027-1032.	1.8	9
25	ERpS294 is a biomarker of ligand or mutational ER $\alpha$ activation and a breast cancer target for CDK2 inhibition. <i>Oncotarget</i> , 2017, 8, 83432-83445.	1.8	11
26	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , 2016, 2, 16007.	5.2	33
27	<sc>DGCR</sc> 8 is essential for tumor progression following <sc>PTEN</sc> loss in the prostate. <i>EMBO Reports</i> , 2015, 16, 1219-1232.	4.5	9
28	FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 23-32.	2.5	8
29	Sources of superoxide/H <sub>2</sub> O <sub>2</sub> during mitochondrial proline oxidation. <i>Redox Biology</i> , 2014, 2, 901-909.	9.0	62
30	A steroid metabolizing gene variant in a polyfactorial model improves risk prediction in a high incidence breast cancer population. <i>BBA Clinical</i> , 2014, 2, 94-102.	4.1	4
31	mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 287-298.	2.5	42
32	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	28.9	1,242
33	First pregnancy events and future breast density: modification by age at first pregnancy and specific VEGF and IGF1R gene variants. <i>Cancer Causes and Control</i> , 2014, 25, 859-868.	1.8	19
34	RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth. <i>Oncotarget</i> , 2014, 5, 5165-5176.	1.8	34
35	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013, 497, 67-73.	27.8	4,075
36	An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. <i>Breast Cancer Research</i> , 2013, 15, R103.	5.0	28

#	ARTICLE	IF	CITATIONS
37	PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis. <i>Bioinformatics</i> , 2012, 28, i640-i646.	4.1	94
38	Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. <i>Breast Cancer Research and Treatment</i> , 2012, 136, 693-703.	2.5	15
39	Targeting Molecular Aberrations in Breast Cancer: Is It about Time?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 186-191.	3.8	0
40	Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 803-810.	2.5	29
41	Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California. <i>BMC Public Health</i> , 2010, 10, 228.	2.9	17
42	ErbB2 Trafficking and Degradation Associated with K48 and K63 Polyubiquitination. <i>Cancer Research</i> , 2010, 70, 3709-3717.	0.9	89
43	A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. <i>Breast Cancer Research</i> , 2010, 12, R85.	5.0	175
44	Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression. <i>Clinical Cancer Research</i> , 2009, 15, 3163-3171.	7.0	110
45	Impact of aging on the biology of breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 65-74.	4.4	165
46	Ageing, oxidative stress and cancer: paradigms in parallax. <i>Nature Reviews Cancer</i> , 2008, 8, 875-879.	28.4	249
47	Destabilization of ERBB2 Transcripts by Targeting 3' UTR Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6. <i>Molecular Cancer Research</i> , 2008, 6, 1250-1258.	3.4	54
48	Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers. <i>Breast Cancer Research</i> , 2007, 9, R59.	5.0	64
49	Enhanced NF- $\kappa$ B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. <i>BMC Cancer</i> , 2007, 7, 59.	2.6	175
50	Novel Pathways Associated with Quinone-Induced Stress in Breast Cancer Cells. <i>Drug Metabolism Reviews</i> , 2006, 38, 601-613.	3.6	19
51	Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 983-994.	2.8	8
52	Breast Cancer Growth Prevention by Statins. <i>Cancer Research</i> , 2006, 66, 8707-8714.	0.9	309
53	Validated High-Throughput Screening of Drug-Like Small Molecules for Inhibitors of ErbB2 Transcription. <i>Assay and Drug Development Technologies</i> , 2006, 4, 273-284.	1.2	12
54	Devious signals from NF- $\kappa$ B driving breast cancer progression. <i>Breast Cancer Online: BCO</i> , 2005, 8, .	0.1	0

#	ARTICLE	IF	CITATIONS
55	Reactivity of zinc finger cysteines: Chemical modifications within labile zinc fingers in estrogen receptor. <i>Journal of the American Society for Mass Spectrometry</i> , 2005, 16, 2017-2026.	2.8	23
56	Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase. <i>Breast</i> , 2005, 14, 256-263.	2.2	13
57	Vitamin K3 (Menadione)-Induced Oncosis Associated with Keratin 8 Phosphorylation and Histone H3 Arylation. <i>Molecular Pharmacology</i> , 2005, 68, 606-615.	2.3	30
58	Activation of nuclear factor- $\kappa$ B (NF $\kappa$ B) identifies a high-risk subset of hormone-dependent breast cancers. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 1130-1144.	2.8	123
59	Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers. <i>Analytical Biochemistry</i> , 2003, 320, 21-31.	2.4	13
60	Geographic excess of estrogen receptor-positive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2003, 12, 1523-7.	2.5	5
61	Redox Control of Zinc Finger Proteins. <i>Methods in Enzymology</i> , 2002, 353, 54-69.	1.0	31
62	Age-associated biomarker profiles of human breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2002, 34, 1318-1330.	2.8	90
63	ErbB2 Activation of ESX gene expression. <i>Oncogene</i> , 2002, 21, 3934-3938.	5.9	35
64	Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 221-236.	2.5	60
65	Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen. <i>Molecular Cancer Therapeutics</i> , 2002, 1, 385-92.	4.1	44
66	Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay. <i>Journal of Clinical Oncology</i> , 2001, 19, 645-656.	1.6	85
67	Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation. <i>Oncogene</i> , 2001, 20, 2101-2111.	5.9	53
68	Ets regulation of the erbB2 promoter. <i>Oncogene</i> , 2000, 19, 6490-6502.	5.9	68
69	A Role for Both Ets and C/EBP Transcription Factors and mRNA Stabilization in the MAPK-dependent Increase in p21 <sup>Cip-1/WAF1/mda6</sup> Protein Levels in Primary Hepatocytes. <i>Molecular Biology of the Cell</i> , 2000, 11, 2915-2932.	2.1	73
70	Preferential Oxidation of Zinc Finger 2 in Estrogen Receptor DNA-binding Domain Prevents Dimerization and, Hence, DNA Binding. <i>Biochemistry</i> , 2000, 39, 8406-8417.	2.5	57
71	Tyrosine Kinase Inhibitors Targeted to the Epidermal Growth Factor Receptor Subfamily. <i>Drugs</i> , 2000, 59, 753-767.	10.9	152
72	Exon 4-encoded acidic domain in the epithelium-restricted Ets factor, ESX, confers potent transactivating capacity and binds to TATA-binding protein (TBP). <i>Oncogene</i> , 1999, 18, 3682-3695.	5.9	26

#	ARTICLE	IF	CITATIONS
73	Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 243-257.	2.5	19
74	Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. <i>Molecular and Cellular Endocrinology</i> , 1998, 146, 151-161.	3.2	55
75	Targeting of Drugs to Solid Tumors Using Anti-Her2 Immunoliposomes. <i>Journal of Liposome Research</i> , 1998, 8, 425-442.	3.3	19
76	Targeting of Liposomes to Solid Tumors: The Case of Sterically Stabilized Anti-Her2 Immunoliposomes. <i>Journal of Liposome Research</i> , 1997, 7, 391-417.	3.3	28
77	ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis. <i>Oncogene</i> , 1997, 14, 1617-1622.	5.9	159
78	HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. <i>Oncogene</i> , 1997, 15, 1513-1525.	5.9	147
79	Oxidant-sensitive protein phosphorylation in endothelial cells. <i>Free Radical Biology and Medicine</i> , 1994, 16, 771-777.	2.9	32
80	Tumor labeling indices of primary breast cancers and their regional lymph node metastases. <i>Cancer</i> , 1993, 71, 3914-3919.	4.1	22
81	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. <i>Breast Cancer Research and Treatment</i> , 1992, 24, 85-95.	2.5	670
82	Stress Response Protein (srp-27) Determination in Primary Human Breast Carcinomas: Clinical, Histologic, and Prognostic Correlations. <i>Journal of the National Cancer Institute</i> , 1991, 83, 170-178.	6.3	150
83	Clinical Pharmacokinetics of Drugs Used in the Treatment of Breast Cancer. <i>Clinical Pharmacokinetics</i> , 1988, 15, 180-193.	3.5	14